AB1288 LONG-TERM AND BOOSTER VACCINATION RESPONSES IN PATIENTS WITH GIANT CELL ARTERITIS AND POLYMYALGIA RHEUMATICA
نویسندگان
چکیده
Background Vaccination remains essential in preventing morbidity of SARS-CoV-2 infections. We previously showed that >10mg/day prednisolone and methotrexate use were associated with reduced antibody concentrations four weeks after primary vaccination patients giant cell arteritis (GCA) polymyalgia rheumatica (PMR) [1] . Objectives Here, we performed a follow-up study to measure the decay over time immunogenicity booster vaccination. Methods GCA/PMR included (BNT162b2 or ChAdOx1) asked again donate blood samples six months (n=24) one month (n=46, BNT162b2 mRNA1273). Data compared age-, sex-, vaccine-matched controls (n=58 n=42, respectively). Results Antibody decreased faster than controls, but this decrease was not treatment during Post-booster comparable between controls. post strongly vaccination, However, fold-change post-booster slight negative correlation post-primary vaccine antibodies. Conclusion These results indicate impaired responses have slightly stronger increases humoral immunity is enough reach similar protection. The immunity, subsequent increase likely impacted by treatment. Rather, these treatments put at an immunogenic disadvantage which fully repaired single This longitudinal stresses importance repeat for used Reference [1]van Sleen Y, van der Geest, Kornelis SM, Reitsema RD, Esen I, Terpstra JH, Raveling-Eelsing E, et al. Humoral cellular rheumatica. RMD open 2022;8(2):e002479. Figure 1. Acknowledgements: NIL. Disclosure Interests Yannick Sleen: None declared, Geest Speakers bureau: Speaker fees from Roche, Grant/research support from: Grant Abbvie, Annemarie Buisman: Maria Sandovici: Debbie Baarle: Elisabeth Brouwer: declared.
منابع مشابه
Polymyalgia rheumatica and giant cell arteritis.
The subjects of the study were 112 patients with rheumatic polymyalgia (RPM) and giant-cell arteritis (GSA). The study shows that RPM and GSA are complicated by cerebral flow disturbances and myocardial infarction. Therapy with prednisolone and non-steroid antiinflammatory drugs reduces the risk of these complications and lethal outcome in patients with RPM and GSA.
متن کاملGiant cell arteritis and polymyalgia rheumatica.
The close relationship between giant cell arteritis and polymyalgia rheumatica has not been clearly explained. These disorders affect the same patient population and often coexist in the same person. Monitoring of the erythrocyte sedimentation rate is a useful tool in both diagnosis and treatment. Management with varying doses of prednisone has proved effective in resolving symptoms.
متن کاملPolymyalgia rheumatica and its links with giant cell arteritis.
Polymyalgia rheumatica (PMR) was defined in 1957 and is linked with giant cell arteritis (GCA) in approximately 25% of cases. The peak incidence is between 60 and 75 years old and is increasing with the ageing population. Polymyalgia rheumatica is a clinical diagnosis without a 'gold standard' serological or histological test and there are other conditions that may mimic PMR. Treatment with a d...
متن کاملPolymyalgia Rheumatica (PMR) — Comparison to Temporal Arteritis (Giant Cell Arteritis)
Giant cell arteritis (a.k.a., Horton’s temporal arteritis) belongs to the vasculitis group of diseases and affects the great vessels, especially branches of the carotid arteries in the head. Polymyalgia rheumatica (PMR) was formerly regarded as an independent disease. Nowadays, due to shared accumulations, it is also commonly assumed that these two diseases are caused by identical pathogeneses,...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of the Rheumatic Diseases
سال: 2023
ISSN: ['1468-2060', '0003-4967']
DOI: https://doi.org/10.1136/annrheumdis-2023-eular.1374